

Baylor
College of
Medicine

**BAYLOR ST. LUKE'S & DAN L DUNCAN
COMPREHENSIVE CANCER CENTER**



**Hematologic Malignancy
Symposium**

Baylor College of Medicine

**THIRD ANNUAL
ACUTE HEMATOLOGIC
MALIGNANCIES SYMPOSIUM**

**SATURDAY MARCH 13, 2021
LIVE VIRTUAL SYMPOSIUM**

PM Poster Session • 12:30-1:15pm CST
Presentations • 8am-4pm CST

For more information, please contact Christina Velasquez at cguerrer@bcm.edu

PLANNING COMMITTEE

Martha P. Mims, MD, PhD

Gustavo Rivero, MD

KEY LECTURERS

Hetty Carraway, MD, MBA, FACP

Cleveland Clinic Lerner College of Medicine of
Case Western Reserve University, Cleveland, OH

Courtney DiNardo, MD

MD Anderson Cancer Center, Houston, TX

Katherine Y. King, MD, PhD

Baylor College of Medicine, Houston, TX

Mark Levis, MD

Johns Hopkins University, Baltimore, MD

Guillermo Garcia Manero, MD

MD Anderson Cancer Center, Houston, TX

Eric Padron, MD

Lee Moffitt Cancer Center, Tampa Bay, FL

Alexander E. Perl, MD

University of Pennsylvania, Perelman Center
for Advanced Medicine, Philadelphia, PA

Uwe Platzbecker, MD

University Hospital, Leipzig, DEU

Daniel A. Pollyea, MD, MS

University of Colorado School of Medicine,
Denver, CO

Gail J. Roboz, MD

Weill Cornell Medical College, New York, NY

David A. Sallman, MD

Lee Moffitt Cancer Center, Tampa Bay, FL

Phillip Scheinberg, MD

Hospital A Beneficência Portuguesa de São Paulo,
São Paulo, BRA

Caroline Watson, MD, PhD

University of Cambridge, Cambridge, UK

Andrew H. Wei, MBBS, PhD

The Alfred Hospital,
Melbourne, AUS

NEEDS

We are witnessing a “revolution” in the therapy of Acute Myelogenous Leukemia [AML]. The incorporation of novel oral hypomethylating agents [HMA], combination of HMA plus BCL-2 inhibitor, anti-CD33 monoclonal antibody, liposomal cytarabine/daunorubicin, FLT3 and IDH inhibitors, among others, have brought enthusiasm to those taking care of AML patients. This accelerated approval and availability of more “directed” AML therapy signals an end for those days, in which a combination of cytarabine plus anthracycline [7+3] was the only induction alternative. As history develops, the 7+3 “one size fits all model” is being replaced by exciting development in genomically inspired therapies resulting in improved induction and survival. Still, we face significant challenges, especially for vulnerable elderly AML patients, who retain dismal outcome. In this AML subgroup, adverse chromosomal and genomic abnormalities are frequently observed, which synergize with comorbid conditions and fragility driving excess in mortality.

During our third symposium, we bring together national and international acclaimed leukemia scientists to discuss recent advances in clonal hematopoiesis, low/high risk myelodysplastic syndrome, targeted AML therapy with emphasis in novel HMA plus BCL-2 inhibitor combination, advances in P53 myeloid malignancies therapies. During our 2021 symposium, we incorporate **State-of-the-Art Lectures** on post induction HMA treatment, mechanisms of FLT3 inhibition resistance and how to manage elderly AML patients. A highly interactive update on HMA plus BCL-2 inhibitor therapy will be followed by a panel discussion on post induction AML maintenance.

Additionally, the symposium will provide important novel development in MDS and AML pathogenesis leading to unique opportunity for clinical trial design ideas.

TARGET AUDIENCE

This course is designed for practicing hematologist, oncologist, physician assistants, basic scientist, nurse practitioners, registered nurses, hematology and oncology fellows, residents and students.

EDUCATIONAL OBJECTIVE

At the conclusion of the activity, participants should be able to:

- Discuss applicability of new FDA-approved agents in targeted therapy for AML and MDS.
- Define current concepts for risk stratification of AML.
- Describe the correlation between clonal hematopoiesis and risk of developing MDS, AML, and cardiovascular disease.
- To understand the role of newly FDA approved medications in post remission AML maintenance.

EDUCATIONAL METHODS

Lectures, panel discussions, case studies, audience response system, as well as questions and answer session.

EVALUATION

Evaluation by questionnaire will address program content, presentation, and possible bias.



ACCREDITATION/CREDIT DESIGNATION

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baylor College of Medicine designates this live activity for a maximum of 6.50 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cizik School of Nursing UTHealth is an approved provider of continuing nursing education by the Texas Nurses Association - Approver, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation. This activity provides 6.50 contact hours on Nursing Continuing Education.

DISCLOSURE

In order to meet the requirements of the Accreditation Council for Continuing Medical Education (ACCME) it is the policy of Baylor College of Medicine that all individuals who are in a position to control the content of a CME course (course director, planning committee members, and faculty) disclose relevant financial relationships with commercial interests. All identified conflicts of interest are managed to help ensure that the educational material is scientifically based, accurate, and objectively presented. Specific disclosure will be made to the participants prior to the educational course.

Audio or videotaping is prohibited without written permission from the Activity Director and the Office of Continuing Medical Education, Baylor College of Medicine, Houston, Texas.

CLAIMING CREDIT

Physician CME Credit,
Nursing, and Other Healthcare
Professional Attendance

After the conference, an email will follow from the Baylor College of Medicine Office of Continuing Medical Education with instructions for completing the evaluation and obtaining your CME, Certificate of Attendance, or CE Certificate (if applicable).

